fluoxazolevir

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namefluoxazolevir
Drug Alias Namehepatitis c virus fusion inhibitors (National Institute of Diabetes and Digestive and Kidney Diseases/University of Kansas)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEnvelope glycoprotein inhibitors
TargetsEnvelope glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Diabetes And Digestive And Kidney Diseases
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of KansasNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis C

Other Information

ATC CodeN/A
Related LinksN/A